European CHMP recommends license extension of Recarbrio (imipenem / cilastatin / relebactam)
The license extension is for treatment of adults with hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), and treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP.
Source:
European Medicines Agency